Amytrx Therapeutics Announces Open Enrollment for Phase 2b Clinical Trial of AMTX-100 CF3, a Promising Anti-Inflammatory Peptide Therapeutic for Atopic Dermatitis ...Middle East

NASHVILLE, June 28, 2023 /PRNewswire/ -- Amytrx Therapeutics, an emerging pharmaceutical company specializing in innovative anti-inflammatory therapies, is pleased to announce the open enrollment for its highly anticipated Phase 2b clinical trial of a topical formulation of AMTX-100 CF3,...

Hence then, the article about amytrx therapeutics announces open enrollment for phase 2b clinical trial of amtx 100 cf3 a promising anti inflammatory peptide therapeutic for atopic dermatitis was published today ( Wednesday 28/06/2023 - 09:29 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Amytrx Therapeutics Announces Open Enrollment for Phase 2b Clinical Trial of AMTX-100 CF3, a Promising Anti-Inflammatory Peptide Therapeutic for Atopic Dermatitis )

Also on site :

• CGTN : l'agenda national de la Chine : principales priorités à la suite des inspections de Xi Jinping et des réunions organisées en 2025
• Protests Push Iran Into a New Phase of Turmoil
• TennRich étend l'écosystème de l'alimentation portable Energizer® à toute l'Europe avec une disponibilité immédiate des stocks